Friday, September 25, 2015

News: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Zimmer Biomet Holdings, Inc.

NEWPORT BEACH, Calif.--()--Acacia Research Corporation (NASDAQ: ACTG) announced today that its Bonutti Skeletal Innovations LLC subsidiary has entered into a settlement and patent license agreement with Zimmer Biomet Holdings, Inc. The agreement resolves litigation that was pending in the United States District Court for the District of Delaware and the United States District Court for the Northern District of Indiana.
ABOUT ACACIA RESEARCH CORPORATION
Founded in 1993, Acacia Research Corporation (NASDAQ: ACTG) is the industry leader in patent licensing. An intermediary in the patent marketplace, Acacia partners with inventors and patent owners to unlock the financial value in their patented inventions. Acacia bridges the gap between invention and application, facilitating efficiency and delivering monetary rewards to the patent owner.
For more information, visit: www.acaciaresearch.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts

Acacia Research Corporation
Rob Stewart, 949-480-8300
Investor Relations
or
Media:
SpecOps Communications
Adam Handelsman, 212-518-7721
President & Founder

Published at Business Wire

News: Cartiva Announces First Patient Treated in Study of Cartiva® Synthetic Cartilage Implant for Pain Associated with Osteoarthritis of the Thumb

Image result for cartiva
ALPHARETTA, Ga.--()--Cartiva, Inc., a developer of innovative solutions for the treatment of cartilage damage, osteoarthritis and other musculoskeletal conditions, announced that the first patient has been treated in its GRIP Study, a multi-center study evaluating the safety and effectiveness of Cartiva Synthetic Cartilage Implant (SCI) in the treatment of first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb. Erin Brown, MD PhD FRCSC, the Co-Principal Investigator of the GRIP Study, performed the surgery at UBC Hospital in Vancouver, British Columbia. This procedure was also the first to utilize this Cartiva implant design, using implants and tools optimized for the specific curvatures of the CMC joint.

“Enrolling the first patient in our feasibility study is an important milestone for our company and the physician community and underscores our commitment to developing innovative and data-supported products for orthopedic extremities patients”
Osteoarthritis of the thumb CMC joint is a common and frequently debilitating condition that affects 8% to 12% of the general population1 and as many as 33% of postmenopausal women2. Also known as thumb basal joint arthritis, osteoarthritis of the CMC joint causes pain, swelling, instability, deformity, loss of motion and weakness, making it difficult to perform a variety of tasks, such as turning doorknobs and opening jars. Current surgical options for later-stage patients for whom conservative treatments have failed include joint fusion, total or partial trapeziectomy or arthroplasty.
Cartiva SCI is a proprietary hydrogel polymer device designed to mimic natural cartilage. The implant is used in the treatment of osteoarthritis in patients with diseased or damaged articular surface in the first CMC joint. Cartiva SCI is implanted in the metacarpal base, where its placement provides replacement for damaged cartilage without requiring the destruction or removal of a patient’s healthy tissue. The design of the Cartiva implant minimizes bone resection and preserves the trapezium and may provide for a quicker and less painful recovery than ligament reconstruction tendon interposition (LRTI) surgery or trapeziectomy. Also, because the procedure preserves normal joint anatomy, LRTI or trapeziectomy remain viable options if a revision is ultimately required. The Cartiva implant is currently available in Europe and Canada.
“We are excited to be the first hospital to enroll a patient in this study,” said Dr. Brown, Clinical Professor and Director of Research, Division of Plastic Surgery at the University of British Columbia. “The Cartiva device is implanted in a quick and straightforward procedure, and has the potential to restore grip and pinch strength following debilitating osteoarthritis of the CMC joint. I look forward to enrolling additional patients and following them on a longer-term basis, which will help examine the potential of this promising technology.”
“Enrolling the first patient in our feasibility study is an important milestone for our company and the physician community and underscores our commitment to developing innovative and data-supported products for orthopedic extremities patients,” said Timothy J. Patrick, president and chief executive officer of Cartiva.
About Cartiva, Inc.
Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative solutions for patients with osteoarthritis, cartilage damage and other musculoskeletal conditions. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates. Additional information is available on the company’s website at www.cartiva.net.
1 Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis. 1966;25: 1-5.
2 Armstrong AL, Hunter JB, Davis TR. The prevalence of degenerative arthritis of the base of the thumb in post-menopausal women. J Hand Surg [Br]. 1994;19: 340-1.

Contacts

Cartiva, Inc.
Peter Pizzo, 770-754-3855
Chief Financial Officer

Published at Business Wire

Thursday, September 24, 2015

News: National Institutes of Health Awards Research Grant to Nanovis Spine to Further Explore Benefits of Nanotube Enhanced FortiCoreTM Spinal Implant Technology

Combination of a deeply porous titanium scaffold with a PEEK center and advanced nanotechnology may reduce healing and fixation times
Nanovis Inc.
Carmel, Ind. (September 22, 2015) – Nanovis Spine today announced the award of a significant research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). The grant will fund advanced research evaluating the potential of Nanovis’ FortiCoreTM implant technology combined with the Company’s developmental nanotube surface technology to accelerate the speed and strength of spinal segment stabilization following spinal fusion procedures.

Nanovis Spine
FortiCore’s deeply porous titanium scaffold is a highly differentiated implant.PEEK Optima® by Invibio is injection molded into the scaffold for exceptional integration, while the PEEK center provides the imaging and mechanical properties preferred by surgeons. Nanovis’ nanotube technology forms durable, nanoscale surface features that have demonstrated the ability to improve bone attachment by generating the body’s natural ability to guide healing and cellular responses.

“In today’s healthcare environment, spinal surgeons are always searching for technologies that can help improve the lives of our patients. With an aging patient population increasingly in need of spinal surgery, advanced technologies that can reduce the time it takes to stabilize spinal segments or enable faster recovery times are in high-demand,” said Jean-Jacques Abitbol, M.D., Past-President NASS, Founder California Spine Group, and Co-Investigator on the grant. “Our prior work using Nanovis’ spinal implant technology is being prepared for publication and suggests the deep pores in the titanium scaffold provide considerably better fixation compared to allograft or PEEK implants. Adding customized nanotube surface technology to the implants has significant potential to further improve results.”
“Support from the NIH is highly selective and underscores the potential of Nanovis’ technology,” said Matt Hedrick, Chief Executive Officer, Nanovis. “Our research and development team includes some of the first scientists to discover
implant nanotechnology alongside innovative and highly accomplished spine surgeons working to develop and deliver commercially viable implants that evolve patient care.”

About Nanovis:
Nanovis’ mission is to lead its selected markets with science-enhanced, life improving technology. Nanovis applies its patented and proprietary technologies to its ever-increasing number of implant platforms. With patents extending well
into the next decade these technologies are expected to fuel growth for years to come. Nanovis’ technology platforms provide differentiated, science-driven advantages to Nanovis’ products that appeal to surgeons and hospital networks attempting to maximize outcomes with the best technology for their patients. Nanovis has three advanced implant technology platforms, the FortiCore implant family; a PEEK spinal implant deeply porous titanium scaffold endplates which
has entered the U.S. market, and an advanced nanotechnology platform under development, and an innovative anti-colonization and antimicrobial implant platform also under development.

Employment:
Nanovis is recruiting for Area Business Director positions. Nanovis also welcomes distributor partners seeking a steady flow of products clearly differentiated by new and advanced technology. Nanovis invites interested individuals to review its website or contact the company directly at 1-877-907-NANO.

This research is supported by the National Institute of Arthritis And Musculoskeletal And Skin Diseases of the National Institutes of Health under Award Number R43AR066979. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
For more information about Nanovis, FortiCore, and other Nanovis technologies please visit
www.nanovisinc.com or call Nanovis at 1-877-907-NANO.

Media Contact:
Levitate
Stacey Holifield
(617) 233-3873
stacey@levitatenow.com

Published at Nanovis Inc Press

News: MARATHON PATENT GROUP'S WHOLLY-OWNED SUBSIDIARY ORTHOPHOENIX, LLC, ENTERS INTO SETTLEMENT AND LICENSE AGREEMENT WITH OSSEON LLC

Marathon Patent Group
LOS ANGELES, CA -- (Marketwired) -- 09/23/15 -- Marathon Patent Group, Inc.(NASDAQ: MARA) ("Marathon"), a patent licensing company, announced today that its wholly-owned subsidiary, Orthophoenix, LLC, has entered into a settlement and license agreement with Osseon LLC. The consideration to be paid by Osseon to Orthophoenix and all other commercial terms of the license agreement are confidential.

The Orthophoenix portfolio consists of patents, which relate to the treatment of bones including fractured and diseased bone elements. Claims coverage includes discharging a material into a bone cavity such that the bone assumes an expanded geometry. In addition to claims covering discharging a material into a bone structure the portfolio included additional patents and associated claims which address bone treatments in which an expandable structure is introduced into a collapsed bone and subsequently manipulated such that the structure forms an expanded geometry inside the bone. Exemplary patents in this portfolio include U.S. Patents 6,248,110, 6,280,456, 6,440,138, 7,044,954, and 6,863,672 with additional foreign patent grants providing International coverage.

About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Marathon Patent Group
Jason Assad
678-570-6791

Source: Marathon Patent Group

News: Conventus Orthopaedics' Quest to Deliver Cage Technology Solution for Fractures Includes New Proximal Radius Product Indication for Innovative 3-Dimensional Fixation

Conventus Orthopaedics, Inc.
MINNEAPOLIS, MN--(Marketwired - September 23, 2015) - Conventus Orthopaedics Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new Conventus Cage™ PR (Promixal Radius) System, designed as an innovative solution to address fractures of the radial head and neck. This new implant, a third approved indication for the company, continues Conventus' momentum in providing solutions for fracture fixation throughout the body based on a self-expanding scaffold.

Utilizing the shape memory properties of nitinol, the Conventus Cage™ expands within the bone creating robust, stable fixation and thus prevents collapse of the fracture repair. Similar to the company's first two products, the Conventus Cage™ DR and Conventus Cage™ PH, the new Conventus Cage™ PR creates a rigid substrate designed to self-expand within the bone to avoid interference with soft tissues and ultimately improve upon pronation and supination. Its self-expanding scaffold provides options to achieve reliable repairs with fewer compromises in peri-articular fractures. The implant is designed to address important limitations of conventional approaches to radial head and neck repairs while allowing for preservation of the bony anatomy and preserving future treatment options.
Paul Buckman, Conventus President and CEO, said, "The approval of this additional indication reflects our commitment to provide more innovative solutions and options for surgeons working to repair orthopedic fractures throughout the body. Our overall goal is to provide a complete platform technology enabling surgeons to treat all trauma and fracture repairs from a 3-dimensional approach."
Conventus designed and developed the proprietary device in close consultation with an expert group of surgeon advisors. The design is aligned with the principles of the Conventus 3-dimensional Cage platform technology, which emphasize preservation of tissues and blood supply at the fracture site, creating a strong foundation by stabilizing bone fragments and facilitating early motion through less invasive procedures.
The Conventus Cage™ PR is indicated for treatment of proximal radial fractures when internal fixation is desired, and fracture fragments are not too numerous and/or too small to be stabilized with the use of the device. For more information regarding use of the device please refer towww.conventusortho.com.
About Conventus Orthopaedics, Inc.
Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a platform technology with less invasive solutions to a broad range of challenging peri-articular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions for fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients' return to normal activities.

CONTACT INFORMATION

News: IMPLANET: New JAZZ Band FDA clearance expands posterior fixation system selection

BORDEAUX, France & BOSTON--()--Regulatory News:
IMPLANET (Paris:IMPL)(Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has received 510(k) regulatory clearance from the Food & Drug Administration (FDA) in the United States removing the intended the use of the JAZZ Band™ platform with the Implanet Spine System. JAZZ may be used with other posterior thoraco-lumbar fixation systems (screws, rods, hooks) available on the market.
Ludovic Lastennet, CEO of Implanet, says: “We had been eagerly awaiting this latest clearance, which represents a major milestone in our development. Surgeons may now utilize their posterior fixation system of choice when incorporating JAZZ into their hybrid constructs. On a clinical level, this clearance will also allow us to initiate extensive multicenter prospective studies in the United States. It sends a strong signal less than a month from the start of major spine surgery conferences, the SRS and NASS annual meetings, and we are confident that this latest clearance will enable us to accelerate our technology’s regulatory process in other countries with substantial market potential.”
This latest FDA clearance follows that obtained in June for the expanded JAZZ Band range, allowing the Company to respond to all surgeon requests through the offer of a comprehensive range covering various diameters.
Next financial press release: revenue for the 3rd quarter of 2015, on 27 October 2015.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.
Ticker: IMPL - ISIN code: FR0010458729

Participation in major upcoming international conferences dedicated to spine surgery
 
30 Sept.-3 Oct. SRS - Scoliosis Research Society Minneapolis, US
14-17 Oct. NASS - North American Spine Society Chicago, US
28-31 Oct. SILACO - Congreso Iberoamericano de Columna Vertebra Lima, Peru

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
or
NewCap
Investor Relations
Florent Alba
Tel.: +33 (0)1 44 71 94 94
or
NewCap
Press Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 98

Published at BusinessWire

News: Life Spine® Announces Issuance of 100th Patent

Image result for Life Spine
HUNTLEY, Ill.--()--Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the company received notice of issuance from the U.S. Patent and Trademark Office (USPTO) regarding U.S. Patent No. 9,138,328, which signifies Life Spine’s 100th patent to date.

The one hundred patents are global in nature and cover the range of Life Spine product lines. The latest patent issuance refers to a radially expandable interbody device and implantation tool, and describes the company’s LONGBOWTM Expandable Lateral Interbody System, the first interbody on the market that expands laterally in-situ, specifically for a direct lateral approach. With the LONGBOW interbody system, surgeons can minimize the need for retraction by as much as 45% compared to currently existing lateral implants, benefitting patients by reducing incision size and potential nerve damage associated with the lateral access approach.
“The issuance of this 100th patent marks a major milestone for Life Spine, which arrived more quickly than anticipated. Perhaps even more important than this particular patent’s issuance is that we have more than 140 additional pending patent applications. Many of these technologies will enable potentially faster recovery times and decreased post-operative pain for spine surgery patients,” said Rich Mueller, Chief Operating Officer at Life Spine.
About Life Spine
Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit http://www.lifespine.com.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
847-884-6117

Published at BusinessWire

News: Orthofix Announces Publication of Data Confirming the Clinical Benefits of Trinity Evolution Cellular Bone Allograft in Foot and Ankle Procedures

Image result for Orthofix International N.V.LEWISVILLE, Texas--()--Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced results from the largest study conducted to date evaluating the safety and effectiveness of their cellular bone allograft (CBA), Trinity Evolution®, in foot and ankle arthrodesis (fusion) procedures. Published online in Foot & Ankle International, patients treated with Trinity Evolution demonstrated per joint fusion rates of 86.8 percent at 12 months follow-up. Additionally, successful fusion significantly correlated with improvements in pain, function, and Quality Of Life (QOL), even in patients with comorbidities such as obesity, diabetes and smoking.
“The goal of arthrodesis in foot and ankle fusion procedures is to decrease pain and improve function and quality of life by reversing disability associated with arthritis, trauma, diabetes and a variety of other conditions”
“The goal of arthrodesis in foot and ankle fusion procedures is to decrease pain and improve function and quality of life by reversing disability associated with arthritis, trauma, diabetes and a variety of other conditions,” said Dr. James Nunley, Professor of Orthopaedic Surgery and Director of Foot & Ankle Surgery at Duke University Medical Center and senior author of the journal article. “This study observed fusion rates using Trinity Evolution that were higher than or comparable to fusion rates in other published studies of autologous corticocancellous bone graft (autograft), a traditional gold standard used in foot and ankle procedures.”
In this prospective, multicenter, open-label clinical study, Trinity Evolution was evaluated in 92 patients undergoing 153 foot and ankle fusion procedures. Compared with previous studies, this trial used prospective enrollment and included patients who were at high risk for bone fusion failure due to age, diabetes or obesity. The primary endpoint was successful fusion based on high resolution CT scans and radiographs assessed by an independent lab. Based on radiographic effectiveness, the study demonstrated a per joint fusion rate of 81.1 percent (124/153) at six months, which increased to 86.8 percent (112/139) at 12 months. Additionally, comorbid factors known to be associated with fusion failure (pseudoarthrosis), such as diabetes, age and obesity, did not have a negative effect in this study. There were no serious adverse events attributable to Trinity Evolution as determined by an independent consultant.
“This study is evidence of our commitment to invest in clinical research to provide physicians the information they need to make the best choices for their patients,” said Orthofix Chief Scientific Officer James Ryaby, Ph.D. “We designed this study to include diabetic, obese and older patients often seen by foot and ankle specialists who might not respond well to traditional allograft and autograft materials. These results support Trinity Evolution as an important alternative to autograft and other bone growth materials in this difficult-to-treat patient population.”
Procedures using autograft often require a second surgical site to harvest the bone. This can cause complications such as pain from the bone removal site and infection. In addition, the quality of the bone harvested can be poor, especially in older individuals or patients with other health issues.
About Trinity Evolution
Trinity Evolution is a cryopreserved CBA from allograft donor bone that facilitates effective bone formation by providing an osteoconductive scaffold, osteoinductive growth factors and osteogenic cells. Trinity Evolution eliminates the need for harvesting autograft from patients, which reduces operating time and expense as well as discomfort and potential complications.
Processed by the Musculoskeletal Transplant Foundation (MTF), a nonprofit organization dedicated to providing quality tissue, Trinity Evolution is the predecessor of Trinity Elite®, a moldable bone graft material that enables physicians to easily control the placement of tissue during procedures. To date there have been more than 135,000 procedures using Trinity Evolution and Trinity Elite.
About Orthofix
Orthofix International N.V. is a diversified, global medical device company focused on improving patients' lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the Company's sales representatives, distributors and its subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as the Musculoskeletal Transplant Foundation and the Texas Scottish Rite Hospital for Children. For more information, please visit www.orthofix.com.
About MTF
The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987, MTF has received tissue from more than 100,000 donors and distributed more than 6 million grafts for transplantation. For more information, visit www.mtf.org.
Forward-Looking Statements
This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.
The forward-looking statements in this release do not constitute guarantees or promises of future performance. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.

Contacts

Orthofix, International N.V.
Investor Relations:
Mark Quick, 214-937-2924
or
Media Relations:
Denise Landry, 214-937-2529

Published at Business Wire